Skip to content

The Impact of Sarcopenia on COPD Exacerbation Admission Outcome and Further Exacerbation Risk

The Impact of Sarcopenia on COPD Exacerbation Admission Outcome and Further Exacerbation Risk

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04885933
Enrollment
43
Registered
2021-05-13
Start date
2018-01-31
Completion date
2020-06-21
Last updated
2021-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Exacerbation, Sarcopenia

Brief summary

Chronic obstructive pulmonary disease (COPD) is more prevalent and has more impact on health status because of progressive air pollution, tobacco smoking and aging society. The COPD prevalence investigation in 2013 by phone call showed at least 6% of the population with more than 40 years-old in Taiwan. It also was the 7th ranking of death causes in Taiwan then. Apart from chronic inflammation in lung and deteriorated lung function, it had extrapulmonary complications, such as cardiovascular problems, osteoporosis and muscle wasting. The concept of sarcopenia was proposed at first in 1989. It increases the risk of falls, disability and lowering life quality. Besides, it increased the mortality risk after admission from acute ward. Thereafter, sarcopenia is one of COPD co-morbidities, which should have great impacts of COPD. The studies showed sarcopenia reduced exercise capacities and worsening dyspnea scores. On the other hand, COPD exacerbation brings significant health burden. But there is limited data about the effect on sarcopenia on COPD exacerbation. We conducted a prospective observational study. We measured skeletal muscle mass and the strength of the used hand grip within 3 days of admission and before discharge. Mortality and exacerbation in one year are the primary end-points

Interventions

DIAGNOSTIC_TESTsarcopenia measurement

BIA for fat free muscle mass hand grasp strength

Sponsors

Far Eastern Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients more than 45 years-old, were admitted due to COPD exacerbation. COPD exacerbation criteria: 1. acute worsening respiratory symptoms without any other causes, And 2. Smoking more than 15 pack-years or the history of noxious gas exposure, And 3. Spirometry reports suggests obstructive ventilatory defect (FEV1/FVC \<0.7) or 4. Attending physicians diagnose as COPD by clinical parameters if spirometry data are not available while enrolling. Definite COPD exacerbation: fulfill 1、2、3 Probable COPD exacerbation: fulfill 1、2、4

Exclusion criteria

1. Significant fluid retention such as edema, pleural effusion or ascites, 2. Patients with permanent pacemaker or implantable cardioverter defibrillator , 3. Morbid obesity with BMI \>34

Design outcomes

Primary

MeasureTime frame
Mortality and exacerbations within 1 year of admission1 years

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026